Lymphadenectomy for the management of endometrial cancer

Katie May, Andrew Bryant, Heather O Dickinson, Sean Kehoe, Jo Morrison

Research output: Contribution to journalArticlepeer-review


Endometrial carcinoma is the most common gynaecological cancer in western Europe and North America. Lymph node metastases can be found in approximately 10% of women who clinically have cancer confined to the womb prior to surgery and removal of all pelvic and para-aortic lymph nodes (lymphadenectomy) is widely advocated. Pelvic and para-aortic lymphadenectomy is part of the FIGO staging system for endometrial cancer. This recommendation is based on non-randomised controlled trials (RCTs) data that suggested improvement in survival following pelvic and para-aortic lymphadenectomy. However, treatment of pelvic lymph nodes may not confer a direct therapeutic benefit, other than allocating women to poorer prognosis groups. Furthermore, a systematic review and meta-analysis of RCTs of routine adjuvant radiotherapy to treat possible lymph node metastases in women with early-stage endometrial cancer, did not find a survival advantage. Surgical removal of pelvic and para-aortic lymph nodes has serious potential short and long-term sequelae and most women will not have positive lymph nodes. It is therefore important to establish the clinical value of a treatment with known morbidity.
Original languageEnglish
Pages (from-to)CD007585
JournalCochrane Database of Systematic Reviews
Issue number1
Publication statusPublished - 2010


Dive into the research topics of 'Lymphadenectomy for the management of endometrial cancer'. Together they form a unique fingerprint.

Cite this